AbstractSummaryProgress in both basic and translational research into the molecular mechanisms of VWD can be seen in multiple fields.Genetics of VWDIn the past several decades, knowledge of the underlying pathogenesis of von Willebrand disease (VWD) has increased tremendously, thanks in no small part to detailed genetic mapping of the von Willebrand Factor (VWF) gene and advances in genetic and bioinformatic technology. However, these advances do not always easily translate into improved management for patients with VWD and low‐VWF levels.VWD and pregnancyFor example, the treatment of pregnant women with VWD both pre‐ and postpartum can be complicated. While knowledge of the VWF genotype at some amino acid positions can aid in knowledge of who may be at increased risk of thrombocytopenia or insufficient increase in VWF levels during pregnancy, in many cases, VWF levels and bleeding severity is highly heterogeneous, making monitoring recommended during pregnancy to optimize treatment strategies.VWF and COVID‐19New challenges related to the consequences of dysregulation of hemostasis continue to be discovered. The ongoing COVID‐19 pandemic has highlighted that VWF has additional biological roles in the regulation of inflammatory disorders and angiogenesis, disruption of which may contribute to COVID‐19 induced vasculopathy. Increased endothelial cell activation and Weibel‐Palade body exocytosis in severe COVID‐19 lead to markedly increased plasma VWF levels. Coupled with impairment of normal ADAMTS13 multimer regulation, these data suggest a role for VWF in the pathogenesis underlying pulmonary microvascular angiopathy in severe COVID‐19.ConclusionWith the increased affordability and availability of next‐generation sequencing techniques, as well as a push towards a multi‐omic approach and personalized medicine in human genetics, there is hope that translational research will improve VWD patient outcomes.